2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118101
    15-Deoxy-Δ12,14-prostaglandin A1 573951-20-9 98%
    15-Deoxy-Δ12,14-prostaglandin A1 is a deoxyanalog of prostaglandins that inhibits NF-κB signaling and induces apoptosis. 15-Deoxy-Δ12,14-prostaglandin A1 inhibits TNF-α-induced upregulation of inflammatory endothelial cell adhesion molecule (CAM) and avoids monocyte arrest.
    15-Deoxy-Δ12,14-prostaglandin A1
  • HY-118160
    PPM-18 65240-86-0 98%
    PPM-18 (NSC 73233), a potent anti-inflammatory agent, inhibits nitric oxide synthase expression. PPM-18 is a potent inhibitor of iNOS expression by blocking the binding of NF-κB to promoter. PPM-18, an analog of Vitamin K, induces autophagy and apoptosis in bladder cancer cells through ROS and AMPK signaling pathways.
    PPM-18
  • HY-118167
    Monoethylglycinexylidide 7728-40-7 98%
    Monoethylglycinexylidide is a metabolite of Lidocain (HY-B0185) via oxidative N-deethylation of Lignocaine by liver cytochrome P-450 enzymes in the liver[1].
    Monoethylglycinexylidide
  • HY-118180
    CAY10595 916047-16-0 98%
    CAY10595 is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki of 10 nM.
    CAY10595
  • HY-118197
    L-669083 130007-52-2 98%
    L-669083 is a leukotriene biosynthesis inhibitor whose structure is based on a mixture of indole and quinoline. In this study, a potent radioiodinated photoaffinity analog of L-689,037, [125I] L-691,678, was developed and characterized for immunoprecipitation studies showing that the quindole series of leukotriene biosynthesis inhibitors directly interact with FLAP. In addition, the results showed that MK-886, L-674,573, and L-689,037 competed with [125I] L-691,678 and [125I] L-669083 for binding to FLAP in a concentration-dependent manner, indicating that these three leukotriene biosynthesis inhibitors share a binding site on FLAP, further demonstrating that FLAP is a suitable target for structurally diverse leukotriene biosynthesis inhibitors.
    L-669083
  • HY-118239
    Re 80 116193-60-3 98%
    Re 80 is an anti-angiogenic agent and is a synthetic retinoid.
    Re 80
  • HY-118299
    JYL 1511 623166-14-3 98%
    JYL 1511 is a partial agonist of vanilloid receptor VR1.
    JYL 1511
  • HY-118316
    GSK223 899758-61-3 98%
    GSK223 is a quinazolinone NOD1 pathway inhibitor with potential anti-inflammatory activity. GSK223 can selectively inhibit IL-8 release under iE-DAP stimulation without affecting IL-8 secretion caused by TNF receptor, TLR2 or NOD2 agonists. GSK223 does not directly inhibit RIP2 kinase activity.
    GSK223
  • HY-118336
    VUF10497 1080623-12-6 98%
    VUF10497 is a potent histamine H4 receptor (H4R) inverse agonist with anti-inflammatory activity.
    VUF10497
  • HY-118408
    D-4418 257892-34-5 98%
    D-4418 serves as a PDE4 inhibitor and is under development as a new anti-inflammatory treatment, primarily targeting asthma and chronic obstructive pulmonary disease.
    D-4418
  • HY-118423
    SJ-3366 195720-26-4 98%
    SJ-3366 (IQP-0410) is a potent inhibitor of HIV nonnucleoside reverse transcriptase. SJ-3366 (IQP-0410) inhibits HIV at sub-nanomolar concentrations primarily through a typical non-nucleoside mechanism.
    SJ-3366
  • HY-118489
    L644711 81997-33-3 98%
    L644711 is an anion transport inhibitor that reduces cell swelling by inhibiting potassium-activated D-aspartate release in astrocytes. L644711 can be used in the study of brain injury and neuroprotection.
    L644711
  • HY-118545
    Butamirate 18109-80-3 98%
    Butamirate is an orally active antitussive agent that acts centrally through the receptors in the brainstem. Butamirate also reduces the resistance in the airways by inhibiting bronchospasm and anti-inflammatory effect. Butamirate inhibits glioblastoma (GBM) growth and STAT3 activity. Butamirate can be used for the study of glioblastoma.
    Butamirate
  • HY-118546
    JNJ-17156516 649551-06-4 98%
    JNJ-17156516 is an orally active, potent, and selective cholecystokinin (CCK)1-receptor antagonist.
    JNJ-17156516
  • HY-118584
    Ro 12-7310 65316-65-6 98%
    Ro 12-7310 is a synthetic retinoid, and can inhibit arachidonic acid release.
    Ro 12-7310
  • HY-118678
    MRS1186 183721-03-1 98%
    MRS1186 is a potent and selective human Adenosine A3 receptor (hA3AR) antagonist, with a Ki of 7.66 nM.
    MRS1186
  • HY-118689
    RA-2 1867107-62-7 98%
    RA-2 is a negative-gating modulator of KCa2/3 channels with an IC50 of 17 nM. RA-2 inhibits bradykinin-induced endothelium-derived hyperpolarization (EDH)-type relaxation in U46619-precontracted rings. RA-2 can help to define the physiologic and pathomechanistic roles of KCa2/3 in the vasculature, central nervous system, and during inflammation.
    RA-2
  • HY-118704
    P-2281 1112994-35-0 99.81%
    P-2281 is a mTOR inhibitor with anticancer and anti-inflammatory efficacies. P2281 inhibits mTOR activity in colon cancer cells. P-2281 suppresses Dextran sulfate sodium salt (HY-116282C) (DSS)-induced colitis by inhibiting T cell function and is efficacious in a murine model of human colitis.
    P-2281
  • HY-118705
    Lagochiline 23554-81-6 98%
    Lagochiline, a diterpene, is a promising hemostatic agent. Lagochiline can be isolated from plants of the Lagochilus kind.
    Lagochiline
  • HY-118725
    Luffariellolide 111149-87-2 98%
    Luffariellolide is an inhibitor of human synovial fluid phospholipase A2 (HSF-PLA2) (IC50=5 μM). Luffariellolide effectively inhibits phorbol ester (PMA)-induced ear edema (ED50=50 μg/ear).
    Luffariellolide
Cat. No. Product Name / Synonyms Application Reactivity